Published in Arch Chir Neerl on January 01, 1977
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol (1992) 4.79
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res (1999) 4.67
Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells. Nature (1983) 3.16
Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res (1992) 2.55
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res (1994) 2.34
Characterization of human c-fes/fps reveals a new transcription unit (fur) in the immediately upstream region of the proto-oncogene. Mol Biol Rep (1986) 2.16
Automated prostate volume determination with ultrasonographic imaging. J Urol (1995) 2.13
Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res (1993) 2.09
Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res (1992) 1.98
Cross-reactivity of anti-DNA antibodies with proteoglycans. Clin Exp Immunol (1984) 1.80
Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol (1996) 1.64
fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. J Clin Invest (1987) 1.63
A practical clinical method for contour determination in ultrasonographic prostate images. Ultrasound Med Biol (1994) 1.60
Fc receptors for mouse IgG1 on human monocytes: polymorphism and role in antibody-induced T cell proliferation. J Immunol (1984) 1.59
Selective detrusor activation by electrical sacral nerve root stimulation in spinal cord injury. J Urol (1997) 1.58
Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer (1995) 1.58
TNM classification of genitourinary tumours 1987--position of the EORTC Genitourinary Group. Br J Urol (1988) 1.55
Evaluation of clinical guidelines for the management of end-stage renal disease in europe: the EU BIOMED 1 study. Nephrol Dial Transplant (2000) 1.43
Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res (1996) 1.41
Quality-of-life assessment in patients after laser prostatectomy. Br J Urol (1997) 1.41
Analysis of the efficacy of measures to reduce pain after subcutaneous administration of epoetin alfa. Nephrol Dial Transplant (1994) 1.39
[Dysmorphic erythrocytes in urinary sediment in differentiating urological from nephrological causes of hematuria]. Ned Tijdschr Geneeskd (1994) 1.39
[The magnitude of the 'anion gap']. Ned Tijdschr Geneeskd (1999) 1.39
Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group. Eur J Cancer (1994) 1.38
Urinary tract infections following laser prostatectomy: is there a need for antibiotic prophylaxis? Br J Urol (1996) 1.38
Comparison of different computer models of the neural control system of the lower urinary tract. Neurourol Urodyn (2000) 1.37
Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate (1988) 1.35
Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol (1997) 1.35
Intraperitoneal administration of recombinant human erythropoietin. Perit Dial Int (1992) 1.34
Variable expression of Ia antigens on the vascular endothelium of mouse skin allografts. Nature (1983) 1.33
The effects of treatment of urinary incontinence in general practice. Fam Pract (1992) 1.32
Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res (1993) 1.29
Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate (1998) 1.27
Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J Histochem Cytochem (1996) 1.25
Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy (1985) 1.23
Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res (1992) 1.23
Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis (1998) 1.23
Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. Eur Urol (1999) 1.22
Controlled trial of pelvic floor exercises in the treatment of urinary stress incontinence in general practice. Br J Gen Pract (1991) 1.22
Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene (2007) 1.21
The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score. J Urol (1996) 1.19
Molecular analysis of multifocal prostate cancer lesions. J Pathol (1999) 1.19
Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res (1999) 1.19
Antiglomerular basement membrane nephritis in beige mice. Deficiency of leukocytic neutral proteinases prevents the induction of albuminuria in the heterologous phase. J Exp Med (1989) 1.18
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol (1993) 1.18
Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. Cancer Res (1991) 1.18
Medication compliance after renal transplantation. Transplantation (1995) 1.18
Hyponatremia due to sodium valproate. Ann Neurol (1998) 1.18
Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer (1997) 1.17
Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res (1991) 1.17
Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother (1991) 1.16
Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother (1992) 1.15
Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis. BMJ (1991) 1.14
High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate (1999) 1.13
Familial glomerulonephritis characterized by massive deposits of fibronectin. Am J Kidney Dis (1995) 1.12
Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol (1993) 1.12
Value of the patient's case history in diagnosing urinary incontinence in general practice. Br J Urol (1991) 1.12
Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol (1995) 1.11
Treatment of mid- and lower ureteric calculi: extracorporeal shock-wave lithotripsy vs laser ureteroscopy. A comparison of costs, morbidity and effectiveness. Br J Urol (1998) 1.11
Decreased PMN accumulation and glomerular damage by clodronate liposome treatment in PMN-dependent anti-GBM nephritis in mice. Exp Nephrol (1997) 1.10
Anti-GBM nephritis in the mouse: severe proteinuria in the heterologous phase. Virchows Arch A Pathol Anat Histopathol (1985) 1.09
Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int (1991) 1.09
Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol (2001) 1.08
Results of the treatment of neurogenic bladder dysfunction in spinal cord injury by sacral posterior root rhizotomy and anterior sacral root stimulation. J Urol (1996) 1.08
Influence of high-intensity focused ultrasound on the development of metastases. Eur Urol (1997) 1.07
Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology (1996) 1.07
A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. Br J Cancer (1996) 1.07
Recurrence of nephrotic syndrome during cyclosporin treatment after renal transplantation. Lancet (1986) 1.06
Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group. Cancer Chemother Pharmacol (1992) 1.05
A sensitive haemolytic assay of mouse complement. J Immunol Methods (1978) 1.05
Grading in superficial bladder cancer. (1). Morphological criteria. Br J Urol (1988) 1.04
A nephritogenic rat monoclonal antibody to mouse aminopeptidase A. Induction of massive albuminuria after a single intravenous injection. J Exp Med (1992) 1.04
Interstitial cystitis: a review of immunological aspects of the aetiology and pathogenesis, with a hypothesis. BJU Int (2000) 1.04
Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-II MPC Study Group. J Pathol (1997) 1.04
Anti-GBM nephritis in the mouse: role of granulocytes in the heterologous phase. Kidney Int (1990) 1.04
BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma. Oncogene (2006) 1.02
Characterization of two Fc receptors for mouse immunoglobulins on human monocytes and cell lines. Scand J Immunol (1987) 1.02
Reliability of the International Prostate Symptom Score in the assessment of patients with lower urinary tract symptoms and/or benign prostatic hyperplasia. J Urol (1996) 1.02
A comparative study of total body irradiation as a method of inducing granulocyte depletion in mice. J Immunol Methods (1984) 1.02
Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview. Urol Int (1990) 1.02
The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J Urol (1996) 1.01
Membranous glomerulonephritis in the mouse. Kidney Int (1983) 1.01
Personality variables involved in chronic prostatitis. Urology (1993) 1.01
Proteolysis induces increased binding affinity of the monocyte type II FcR for human IgG. J Immunol (1989) 1.01
Spontaneous renal decapsulation with excessive fluid leakage after transplantation. N Engl J Med (1979) 0.99
A comparison of the cytolytic action of guinea pig and rabbit complement on sensitized nucleated mouse cells. J Immunol (1973) 0.99
Epidemiology of prostate cancer. Eur Urol (1996) 0.99
Variability of pressure-flow analysis parameters in repeated cystometry in patients with benign prostatic hyperplasia. J Urol (1995) 0.99
Establishment and characterization of five new human renal tumor xenografts. Am J Pathol (1992) 0.99
Extracorporeal shock wave lithotripsy for large renal calculi: the role of ureteral stents. A randomized trial. J Urol (1991) 0.99
Improved reliability of uroflowmetry investigations: results of a portable home-based uroflowmetry study. Br J Urol (1996) 0.97
Hyperacute rejection of skin allografts in the mouse by the administration of alloantibody and rabbit complement. J Immunol (1973) 0.97
Antigen-specificity of antibodies bound to glomeruli of mice with systemic lupus erythematosus-like syndromes. Lab Invest (1993) 0.97